

Disclosures

Personal Commercial (33)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Alnylam	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Ambry Genetics	Speaker's Bureau	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Amicus	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Audentes	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Congenital Heart Disease and Pediatric Cardiology</i>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Biocardia	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bristol Myers Squibb	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Chiesi	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Daxor	Stock	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Daxor	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Freeline	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
HeartBeam	Research/Research Grants	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>
Innolife	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Myokardia	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis	Consultant Fees/Honoraria	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
NS Pharma	Speaker's Bureau	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Nuwellis	Stock	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Nuwellis	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Pfizer	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Pfizer Inc	Speaker's Bureau	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Protalix	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sangamo	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sanofi Genzyme	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sanofi Genzyme	Speaker's Bureau	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Stealth Biotherapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Tenaya	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
V Wave	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Veru	Research/Research Grants	Significant (>= \$5,000)	<i>Other</i>
Yendii	Ownership Interest/Partnership/Principal	None (\$0)	<i>Other</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 1/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 1/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 1/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 1/3/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.